Democratic presidential candidate Hillary Clinton (Carolyn Kaster, The Associated Press)
Re: “Drug industry shrugs at Clinton’s plan to reduce costs,” Sept. 23 news story.
Among other issues in Hillary Clinton’s drug plan, as reported by The Associated Press, one issue bothered me. According to The AP, “It adds some newer ideas, including requiring drugmakers to invest a set portion of profits into research, rather than TV and print advertisements.”
I hope the actual wording is very clear to avoid unintended consequences. Do generic drugmakers have to adhere to this? If so, it could spell the end of generic drugmakers. The generics are good at low-cost pharmaceutical manufacturing, not research and development.
This requirement could force the generics out of business.
Otto Buhler, Boulder
This letter was published in the Sept. 25 edition.
Submit a letter to the editor via this form or check out our guidelines for how to submit by e-mail or mail.
